Abstract
Prolyl oligopeptidase (POP) is a serine protease that cleaves peptides shorter than 30-mer at the carboxyl side of an internal proline. POP has been proposed to be involved in some pathologies including mood disorders and neurodegenerative diseases. However, the physiological role of POP remains unknown. To validate POP as a drug target, it is essential to obtain a thorough understanding of its function in vivo. Identification of physiological substrates and products of POP is an important step towards this goal. Recent peptidomic studies have revealed some biological substrates of POP and have given information about the in vivo consequences of POP inhibition. The aim of this review it is to evaluate new advances in this research area and to critically confront these data with initial conclusions and proposals. It seems that substantial activity of POP occurs intracellularly in contrast to the previously proposed role of this peptidase on the direct degradation of extracellular neuropeptides.
Keywords: Prolyl oligopeptidase, prolyl endopeptidase, peptidomics, neuropeptides, peptide metabolism, Somatostatin-28, JTP-4819, GABA, Ac-SDKP, Chronic Obstructive Pulmonary Disease, Radioimmunoassay, iTRAQ, Neurogranin, Haemoglobin, Prosaas
CNS & Neurological Disorders - Drug Targets
Title: Hunting for Peptide Substrates of Prolyl Oligopeptidase: Classical Versus Non-Classical Bioactive Peptides
Volume: 10 Issue: 3
Author(s): Jofre Tenorio-Laranga, Pekka T. Mannisto and J. Arturo Garcia-Horsman
Affiliation:
Keywords: Prolyl oligopeptidase, prolyl endopeptidase, peptidomics, neuropeptides, peptide metabolism, Somatostatin-28, JTP-4819, GABA, Ac-SDKP, Chronic Obstructive Pulmonary Disease, Radioimmunoassay, iTRAQ, Neurogranin, Haemoglobin, Prosaas
Abstract: Prolyl oligopeptidase (POP) is a serine protease that cleaves peptides shorter than 30-mer at the carboxyl side of an internal proline. POP has been proposed to be involved in some pathologies including mood disorders and neurodegenerative diseases. However, the physiological role of POP remains unknown. To validate POP as a drug target, it is essential to obtain a thorough understanding of its function in vivo. Identification of physiological substrates and products of POP is an important step towards this goal. Recent peptidomic studies have revealed some biological substrates of POP and have given information about the in vivo consequences of POP inhibition. The aim of this review it is to evaluate new advances in this research area and to critically confront these data with initial conclusions and proposals. It seems that substantial activity of POP occurs intracellularly in contrast to the previously proposed role of this peptidase on the direct degradation of extracellular neuropeptides.
Export Options
About this article
Cite this article as:
Tenorio-Laranga Jofre, T. Mannisto Pekka and Arturo Garcia-Horsman J., Hunting for Peptide Substrates of Prolyl Oligopeptidase: Classical Versus Non-Classical Bioactive Peptides, CNS & Neurological Disorders - Drug Targets 2011; 10 (3) . https://dx.doi.org/10.2174/187152711794653841
DOI https://dx.doi.org/10.2174/187152711794653841 |
Print ISSN 1871-5273 |
Publisher Name Bentham Science Publisher |
Online ISSN 1996-3181 |
- Author Guidelines
- Graphical Abstracts
- Fabricating and Stating False Information
- Research Misconduct
- Post Publication Discussions and Corrections
- Publishing Ethics and Rectitude
- Increase Visibility of Your Article
- Archiving Policies
- Peer Review Workflow
- Order Your Article Before Print
- Promote Your Article
- Manuscript Transfer Facility
- Editorial Policies
- Allegations from Whistleblowers
Related Articles
-
DYRK1A: A Potential Drug Target for Multiple Down Syndrome Neuropathologies
CNS & Neurological Disorders - Drug Targets Radiopharmaceutical: Revolutionary Agents for Diagnosis
Current Radiopharmaceuticals Real Time Analysis of Neurotransmitters in the Brain Using a Micro-Electrode System
Current Neurovascular Research Alpha-1-Adrenergic Receptor Blockade Modifies Insulin-Regulated Aminopeptidase (IRAP) Activity in Rat Prostate and Modulates Oxytocin Functions
Drug Metabolism Letters Neuropharmacology of the Endocannabinoid Signaling System-Molecular Mechanisms, Biological Actions and Synaptic Plasticity
Current Neuropharmacology Polyisoprenylation Potentiates the Inhibition of Polyisoprenylated Methylated Protein Methyl Esterase and the Cell Degenerative Effects of Sulfonyl Fluorides
Current Cancer Drug Targets New Trends in Fiber-Optic Chemical and Biological Sensors
Current Analytical Chemistry Neurotoxicity Induced by Mephedrone: An up-to-date Review
Current Neuropharmacology Metal Catalyzed Oxidation of Alpha-Synuclein – A Role for Oligomerization in Pathology?
Current Alzheimer Research Critical Enzymes Involved in Endocannabinoid Metabolism
Protein & Peptide Letters Glycogen Synthase Kinase-3 (GSK-3) Inhibitors for the Treatment of Alzheimers Disease
Current Pharmaceutical Design From Rapid to Delayed and Remote Postconditioning: The Evolving Concept of Ischemic Postconditioning in Brain Ischemia
Current Drug Targets Pathophysiology of Blood-Spinal Cord Barrier in Traumatic Injury and Repair
Current Pharmaceutical Design MiR-138 and MiR-135 Directly Target Focal Adhesion Kinase, Inhibit Cell Invasion, and Increase Sensitivity to Chemotherapy in Cancer Cells
Anti-Cancer Agents in Medicinal Chemistry Current Status and Perspectives in Peptide Receptor Radiation Therapy
Current Pharmaceutical Design Nature Against Depression
Current Medicinal Chemistry Activation of Brain Endothelium by Soluble Aggregates of the Amyloid-β Protein Involves Nuclear Factor-κB
Current Alzheimer Research Strategies to Improve the Killing of Tumors Using Temozolomide: Targeting the DNA Repair Protein MGMT
Current Medicinal Chemistry Cyclic AMP Enhancers and Aβ Oligomerization Blockers as Potential Therapeutic Agents in Alzheimers Disease
Current Alzheimer Research The Ubiquitin-Proteasome Pathway and Resistance Mechanisms Developed Against the Proteasomal Inhibitors in Cancer Cells
Current Drug Targets